KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Dec 2024 value amounting to $257.5 million.

  • Vertex Pharmaceuticals' Shares Outstanding (Weighted Average) fell 0.66% to $256.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $256.4 million, marking a year-over-year decrease of 0.66%. This contributed to the annual value of $257.5 million for FY2024, which is 0.06% down from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Shares Outstanding (Weighted Average) stood at $257.5 million for FY2024, which was down 0.06% from $257.7 million recorded in FY2023.
  • Vertex Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $260.0 million during FY2020, with a 5-year trough of $254.3 million in FY2021.
  • Over the past 3 years, Vertex Pharmaceuticals' median Shares Outstanding (Weighted Average) value was $257.5 million (recorded in 2024), while the average stood at $257.3 million.
  • In the last 5 years, Vertex Pharmaceuticals' Shares Outstanding (Weighted Average) rose by 1.12% in 2020 and then declined by 2.23% in 2021.
  • Yearly analysis of 5 years shows Vertex Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $260.0 million in 2020, then declined by 2.23% to $254.3 million in 2021, then increased by 0.96% to $256.7 million in 2022, then increased by 0.39% to $257.7 million in 2023, then declined by 0.06% to $257.5 million in 2024.